MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study

benzinga.com/news/health-care/25/09/47786055/mbx-biosciences-experimental-drug-shows-promise-hypoparathyroidism-study

MBX Biosciences, Inc. (NASDAQ:MBX) stock traded higher on Monday after the company released clinically meaningful and statistically significant topline results from the once-weekly canvuparatide Phase 2 trial..
On Monday, the company announced that once-weekly canvuparatide achieved the…

This story appeared on benzinga.com, 2025-09-22 12:28:36.
The Entire Business World on a Single Page. Free to Use →